Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease | Metrics - Cureus
Detecting the silent epidemic of fatty liver disease
Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter - ScienceDirect
CAP cutoff values for the diagnosis of steatosis grades ≥S1, ≥S2, and ≥S3 | Download Table
Presentación de PowerPoint
Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
PDF) Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
Transient elastography versus liver biopsy: discordance in evaluations for fibrosis and steatosis from a pathology standpoint | Modern Pathology
Clinical and Molecular Hepatology
Frontiers | Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
Clinical and Molecular Hepatology
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease - ScienceDirect
Frontiers | Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
Diagnostics | Free Full-Text | Ultrasound-Based Diagnostic Methods: Possible Use in Fatty Liver Disease Area
Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study
Non-invasive tests of non-alcoholic fatty liver disease | Chinese Medical Journal
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine
PDF) FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19
Frontiers | Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? | SpringerLink
